A Study of ERAS-601 in People With Chordoma
Trial Parameters
Brief Summary
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Have histologically confirmed chordoma that is not dedifferentiated or poorly differentiated subtype. * Have progressive disease per RECIST 1.1 defined by +20% change between any two scans in the 9 months prior to enrollment. * Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 * Recovered from acute, clinically significant toxicities associated with current/recent treatments to acceptable baseline status * Screening laboratory values must meet the following criteria and should be obtained within 30 days prior to study treatment: * Absolute neutrophil count (ANC) ≥ 1.5 x 103/m * Platelet count ≥ 75 × 103/mL without symptomatic bleeding * Hemoglobin \> 9 g/dL * Serum electrolytes (sodium, potassium, magnesium, phosphorus, calcium) Grade ≤1 or within the institutional ranges of normal. If clinically appropriate, electrolytes may be corrected, and values reassessed prior to enrollment. * AST and ALT ≤ 2.5 × ULN or ≤ 5 × U